TheraRadar
← Back
Data updated: Jul 17, 2026

VITRUVIAS THERAP

Generics
Pharmaceuticals

VITRUVIAS THERAP is a generic drug manufacturer with 2 FDA-approved products.

2017
Since
2
Drugs
-
Trials
0
New Drugs (2yr)

VITRUVIAS THERAP's Key Drugs

VITRUVIAS THERAP's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

VITRUVIAS THERAP's Recent FDA Approvals

New NDA/BLA approvals for VITRUVIAS THERAP over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

VITRUVIAS THERAP's Therapeutic Areas

Disease areas where VITRUVIAS THERAP has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

VITRUVIAS THERAP Pipeline Snapshot

Active clinical trials for VITRUVIAS THERAP across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling